NCT03018405: A trial that was reported late by Celyad Oncology SA
This trial has reported, although it was 135 days late in doing so.
Full data
| Full entry on ClinicalTrials.gov | NCT03018405 |
|---|---|
| Title | A Multi-national, Open-label, Dose Escalation Phase I Study to Assess the Safety and Clinical Activity of Multiple Administrations of NKR-2 in Patients With Different Metastatic Tumor Types (THINK - THerapeutic Immunotherapy With NKR-2) |
| Results Status | Reported (late) |
| ACT or pACT? | This is what FDAAA officially calls a "probable Applicable Clinical Trial" |
| Start date | Dec. 31, 2016 |
| Completion date | May 31, 2021 |
| Required reporting date | May 31, 2022, midnight |
| Actual reporting date | Oct. 13, 2022 |
| Date last checked at ClinicalTrials.gov | Dec. 5, 2025 |
| Days late | 135 |